Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 6—June 2020
Research

Effectiveness and Tolerability of Oral Amoxicillin in Pregnant Women with Active Syphilis, Japan, 2010–2018

Takeshi Nishijima, Kei KawanaComments to Author , Ichio Fukasawa, Naoko Ishikawa, Melanie M. Taylor, Hiroshige Mikamo, Kiyoko Kato, Jo Kitawaki, Tomoyuki Fujii, and Women’s Health Care CommitteeJapan Society of Obstetrics and Gynecology
Author affiliations: National Center for Global Health and Medicine, Tokyo, Japan (T. Nishijima); World Health Organization Regional Office of the Western Pacific, Manila, the Philippines (T. Nishijima, N. Ishikawa); Nihon University School of Medicine, Tokyo, Japan (K. Kawana); Dokkyo Medical University, Tochigi, Japan (I. Fukasawa); World Health Organization, Geneva, Switzerland (M.M. Taylor); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (M.M. Taylor); Aichi Medical University, Aichi, Japan (H. Mikamo); Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan (K. Kato); Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan (J. Kitawaki); Graduate School of Medicine, The University of Tokyo, Tokyo, Japan (T. Fujii)

Main Article

Table 4

Serologic outcomes of pregnant women with active syphilis treated with amoxicillin or ampicillin, Japan, 2010–2018, by delivery, 6 months after treatment, and 1 year after treatment*

Patient group No./total (%) with >4-fold decrement in RPR titer
By delivery 6 months after treatment 1 year after treatment
All 35/71 (49) 41/77 (53) 46/56 (82)
Live birth without CS diagnosis 27/54 (50) 29/54 (54) 31/39 (80)
CS cases† 5/13 (39) 6/15 (40) 9/11 (82)
Early syphilis 15/26 (58) 20/30 (67) 21/23 (91)
Late syphilis 20/45 (44) 21/47 (45) 25/33 (76)
Amoxicillin 27/58 (47) 32/63 (51) 36/44 (82)
Ampicillin 8/13 (62) 9/14 (64) 10/12 (83)
Japanese 34/66 (52) 39/72 (54) 44/52 (85)
Non-Japanese 1/5 (20) 2/5 (40) 2/4 (50)
Started syphilis treatment >60 days before delivery 32/55 (58) 32/55 (58) 35/43 (81)
Started syphilis treatment <60 days before delivery 0 5/17 (29) 6/8 (75)

*CS, congenital syphilis; RPR, rapid plasma reagin.
†CS cases include newborns with CS diagnoses, miscarriages, and stillbirths.

Main Article

Page created: May 18, 2020
Page updated: May 18, 2020
Page reviewed: May 18, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external